JGC
ATNM icon

J. Goldman & Co’s Actinium Pharmaceuticals ATNM Stock Holding History

J. Goldman & Co’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,500
Closed -$79.9K – 345
2023
Q3 		$79.9K Hold
13,500
– – ﹤0.01% 334
2023
Q2 		$100K Sell
13,500
-28,728
-68% -$244K ﹤0.01% 341
2023
Q1 		$399K Sell
42,228
-37,880
-47% -$400K 0.02% 283
2022
Q4 		$853K Sell
80,108
-68,630
-46% -$696K 0.04% 235
2022
Q3 		$1.1M Buy
+148,738
New +$925K 0.05% 248
2020
Q4 		– Sell
-168,749
Closed -$1.64M – 367
2020
Q3 		$1.64M Buy
168,749
+97,069
+135% +$1.07M 0.11% 182
2020
Q2 		$756K Buy
+71,680
New +$543K 0.05% 206

Other funds holding ATNM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

J. Goldman & Co's ATNM Position: Q4 2023 in Review

J. Goldman & Co sold out of Actinium Pharmaceuticals (ATNM) in Q4 2023, closing a stake of 13,500 shares — an estimated $79.9K sold.

J. Goldman & Co first reported a position in ATNM in Q2 2020 and held it in 7 quarters. The position peaked at $1.64M in Q3 2020. 59 funds tracked by Wall St. Rank hold ATNM as of Q4 2023.

  • J. Goldman & Co reported no remaining Actinium Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • J. Goldman & Co sold 13,500 Actinium Pharmaceuticals shares in Q4 2023, an estimated $79.9K.
  • J. Goldman & Co first reported a position in Actinium Pharmaceuticals in Q2 2020 and held it in 7 quarters.
  • J. Goldman & Co's Actinium Pharmaceuticals position peaked at $1.64M in Q3 2020.
  • 59 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.